Biobanks | Sep 20071
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
Regulatory Agencies (FDA, EMEA, MHLW, WHO, DHHS, CDC)
PLarge PharmaOther PharmaIntegrated BiotechResearch Biotech
Drug Developers Patients/Consumers
DistMfrDevResearch
Large University/Medical SchoolsSpecialized Research CentersOther Academic Medical Research Centers (AMRC’s) and Biobanks
Integrated Delivery NetworksSpecialized HospitalsIndependent Community HospitalsPhysician Private Practices
Research Funding Agencies (NIH etc, EU FP, AP Gov'ts)
Equipment & Device CompaniesApplications ProvidersIT Infrastructure and Service ProvidersDiagnostics Manufacturers
Solution Providers Government (CMS, EU, AP) Private (US HMO’s: CIGNA, AETNA, Oxford Health, WellPoint, Kaiser Permanente, ...)Employers (Corporations)
Government Agencies
Patient (Genetic Alliance etc)Industry and Academic (e.g., Personalized Medicine Coalition, EPPOSI)
Advocacy Groups
The Role of Biobanks should be viewed in the context of the Healthcare and Life Sciences Ecosystem with the Patient/Consumer in the Center
Research Institutions
Healthcare Providers
Government Research
Payers
CROs (e.g. Quintiles, Parexel, Covance, Imaging Core Labs)
Clinical Trial Support
Biobanks | Sep 20072
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
Clinical Patient Data must be integrated with Imaging, Genotypic, and Environmental Data to discover Biomarkers and to enable Biomarker based Pharma R&D and “Personalized Clinical Care”
Information Based Medicine
Bio
med
ical
Im
age
Dat
a
BasicResearch
Bio-Pharma R&D
ClinicalDelivery
Clin
ical
D
ata
HT
Res
earc
h D
ata
Env
iro.’a
lD
ata
Phenotype Genotype Environment
Molecular-level understanding of disease
Enabling development of Targeted Treatment
Solutions
Improving efficacy, safety and cost-efficiency of
patient care
PersonalizedClinical Care
Val
ue
Biobanks toBiomarkers
Biobanks | Sep 20073
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
Medical/Biological Research (Biobank) Projects are aimed at the Discovery of new Biomarkers
The Mayo Clinic: Transform the effectiveness and economics of health care, by focusing on new techniques to harness patient data to improve diagnoses; deep computing power to model diseases to find cures; and new devices to access information to transform how patients and physicians interact, leading to more personalized care. Latest Step: MCLSS
Karolinska Institutet: The KI Biobank is an asset for biomedical research within fields such as genetics, functional genomics, as well as genetic and molecular epidemiology. KI Biobank benefit combines significant tissue collections and large national databases with epidemiological information. The robust and scalable Biobank Information Management System (BIMS) can readily accommodate a growing number of new projects and diverse data sources.
iCAPTURE/University of British Columbia: Determine the relationships between genomic, phenotypic, and environmental data in relation to heart, lung, and blood vessel disease. Focus on Imaging and Biomarker Discovery, including Tissue Rejection Biomarkers
In addition: AMC (Amsterdam), Danubian Biobank (Regensburg), St. Justine (Montreal), NIH Lupus Project, Taiwan Biobank ...
Biobanks | Sep 20074
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
WS Information Integrator
WebSphere
Data Discovery and Query Builder
Query/Visualization/Analysis
MedicalInformationRepository
LaboratoryResults and
Reports
ClinicalNotes(20 M)
CodedDiagnostics
GeneExpression
CDA/XML
MAGE-ML
ETL
Replication
PatientDemo-
graphics
In the Medical Research Space, IBM has been partnering with leading institutions since 2002
MAYO Clinic High Level Architecture
Biobanks | Sep 20075
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
BIM
S S
ervi
ces
BIM
S B
acke
nd A
rchitec
ture
In Partnership with IBM, KI Biobank developed the BIMS Architecture .....
StudyMgmt
SampleMgmt
DataQuery
DataCollection
Data Integration
BIM
S S
uppor
t Ser
vice
s
SecurityServices
PublicInfo
DataAnalysis
AdminServices
Original Data Sources
BIMS Data Repository
DataCategorization
6
IBM Global Business Services
© 2006 IBM Corporation
... recently enhanced to include Image Data Management (to address Stockholm Brain Institute IT requirements)
6
BIM
S S
ervice
sBIM
S S
ervice
sBIM
S S
ervice
sBIM
S B
acke
nd A
rchite
cture
BIM
S B
acke
nd A
rchite
cture
StudyMgmnt
DataQueryData
Query
Existing Data Integration
BIM
S S
uppor
t Ser
vice
s
SecurityServicesSecurityServices
PublicInfo
AdminServicesAdmin
Services
Existing Data Sources (Structured)
BIMS Data RepositoryBIMS Data Repository
DataAbstractionDataAbstraction
SampleMgmntSampleMgmnt
DataCollection
DataCollection
DataAnalysis
Web Portal
Content Manager
InformationIntegrator Content Edition
Records Manager
Biobanks | Sep 20077
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
IBM Healthcare and Life Sciences Biobank Summits
• Nice, France: March 2004• - 40 attendees• - 30+ institutions
• Tarrytown, NY: November 2004• - 100+ attendees• - 90+ institutions
Biobanks | Sep 20078
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
2005 WW Biobank Summits III and IV:Strategies to Address Next Generation Challenges for Biobanking
24-26 May 2005
The Nobel ForumKarolinska Institutet
Stockholm, Sweden
8-9 November 2005
“Quest for a Cure”Cooperation with NCI
Washington, DC
Web Resource: http://www.biobankcentral.org/public/index.php
Biobanks | Sep 20079
IBM Healthcare & Life Sciences
© Copyright IBM Corporation 2007
By bringing together the various Stakeholders, IBM is hoping that the Imaging Biomarker Summits will accelerate the Transformation of Healthcare and Life Sciences
• The Imaging Biomarker Summits provide a Forum for the exchange of ideas and best practices related to Biomarker enabled Pharma R&D, with special emphasis on the impact of Imaging technologies. They are attended by representatives from Pharma, Biotech, Government & Academic Medical Research Centers, FDA, Medical Device Manufacturers and other IBM Partners.
• The Imaging Biomarker Summit feature presentations, facilitated Workshops, and Panel Discussions led by established academic and industry leaders
• Presentations at IBS I were given by- Peter Corr, Pfizer R&D- Carol Kovac, IBM HC & LS- Gerd Schmitz, Danubian Biobank- George Mills, FDA - Larry Schwartz, MSK Cancer Center
• Presentations at IBS II were be given by- Andrew von Eschenbach, FDA- Pfizer, Genentech, Merck & FNIH- NCI, UCLA, JHU, Wash U, U MD- GE HC, Siemens, Philips- IBM, VirtualScopics, Kitware
• Discussions of Imaging Biomarkers in Oncology, Neurosciences, and Cardiovascular disease
• Workshops, Panel Discussions- Imaging Biomarker Research / Discovery- Imaging Biomarkers in Pharma R&D- IT Standards and Architectures
• IBS Events 2007: IBS III (Nice) Jan 24-26, IBS IV (Japan) July 14-16
Participating OrganizationsPfizer, Merck, Novartis, J&J, AZ, Amgen, Roche, BMS, B-I, GSK, Roche/Chugai, Genentech, Wyeth, Astellas, Takeda, Eisai, PhRMA, FDA, GE, Siemens, Philips, NCI, NIH, NIST, FNIH, KI, Yale, MSK, Scripps, UCLA, JHU, Wash U, U MD, U Texas, Danubian Biobank, iCapture, Taiwan NCTU, NIRS, Tokyo Univ ...
Philadelphia | 26-27 June 2006Philadelphia | 26-27 June 2006
AMAGI | July 2007
Nice – La Gaude | January 24-26, 2007
IBS II
IBS III
IBS IV
Top Related